Skip to content
Metrizoic acid
Isopaque (metrizoic acid) is a small molecule pharmaceutical. Metrizoic acid was first approved as Isopaque 280 on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Calcium
+
Meglumine
+
Metrizoic acid
Tradename
Company
Number
Date
Products
ISOPAQUE 280GE HealthcareN-017506 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V08: Contrast media
— V08A: X-ray contrast media, iodinated
— V08AA: Watersoluble, nephrotropic, high osmolar x-ray contrast media
— V08AA02: Metrizoic acid
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMETRIZOIC ACID
INN—
Description
Metrizoic acid is a monocarboxylic acid. It has a role as a radioopaque medium.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I
Identifiers
PDB—
CAS-ID1949-45-7
RxCUI—
ChEMBL IDCHEMBL1736
ChEBI ID34847
PubChem CID2528
DrugBankDB09346
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,689 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details